Literature DB >> 299948

In vitro evidence of cell-mediated immunity after exposure of mice to both live and inactivated rabies virus.

T J Wiktor, P C Doherty, H Koprowski.   

Abstract

Mice exposed to live or beta-propiolactone-inactivated rabies virus generated a strong, specific cell-mediated cytotoxic response which was generally maximal 6 days after inoculation. Release of 51Cr was apparently a function of immune thymus-derived lymphocytes (T cells) because it was abrogated by prior incubation of spleen cells with anti-thymus antiserum and complement but was undiminished by passage of spleen cells through nylon-wool columns. Cytotoxicity was always maximal for interactions in which thymus-derived cells and targets shared H-2 genes but, unlike the situation found in other assays of this type, considerable lysis of allogeneic, virus-infected target cells may also occur. Perhaps the most significant finding from these experiments is that an inactivated virus has been shown to stimulate a potent cytotoxic thymus-derived cell response. Manipulation of this experimental model may allow analysis of the antigens required for stimulation of cell-mediated immunity. A more practical consequence may be the development of more rational protocols for postexposure vaccination against rabies. Prior treatment of mice with antirabies antibody severely depressed the generation of cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 299948      PMCID: PMC393254          DOI: 10.1073/pnas.74.1.334

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Immunization schedules for the new human diploid cell vaccine against rabies.

Authors:  S A Plotkin; T J Wiktor; H Koprowski; E I Rosanoff; H Tint
Journal:  Am J Epidemiol       Date:  1976-01       Impact factor: 4.897

Review 2.  T-cell-mediated immunopathology in viral infections.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Transplant Rev       Date:  1974

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells.

Authors:  P Perlmann; H Perlmann; H Wigzell
Journal:  Transplant Rev       Date:  1972

5.  Antigenic and immunogenic properties of components contained in rabies virus-infected tissue culture fluids.

Authors:  H D Schlumberger; T J Wiktor; H Koprowski
Journal:  J Immunol       Date:  1970-08       Impact factor: 5.422

6.  Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin.

Authors:  T J Wiktor; F Sokol; E Kuwert; H Koprowski
Journal:  Proc Soc Exp Biol Med       Date:  1969-07

7.  Pathogenesis of rabies in immunodeficient mice.

Authors:  M M Kaplan; T J Wiktor; H Koprowski
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

8.  Peritoneal macrophages as target cells for measuring virus-specific T cell mediated cytotoxicity in vitro.

Authors:  R M Zinkernagel; P C Doherty
Journal:  J Immunol Methods       Date:  1975-09       Impact factor: 2.303

9.  Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity.

Authors:  P C Doherty; R V Blanden; R M Zinkernagel
Journal:  Transplant Rev       Date:  1976

10.  H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;.

Authors:  R M Zinkernagel; P C Doherty
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  31 in total

1.  Role of host immune response in the development of either encephalitic or paralytic disease after experimental rabies infection in mice.

Authors:  Y Iwasaki; W Gerhard; H F Clark
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

2.  Rabies pathogenesis.

Authors:  F A Murphy
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

Review 3.  The use of immunosome technology for vaccines against rabies and other viral diseases.

Authors:  P Sureau; P Perrin
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

4.  Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.

Authors:  Milosz Faber; Rojjanaporn Pulmanausahakul; Suchita S Hodawadekar; Sergei Spitsin; James P McGettigan; Matthias J Schnell; Bernhard Dietzschold
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Rapid immunoenzymatic technique for titration of rabies antibodies IgG and IgM results.

Authors:  P Atanasiu; V Savy; C Gibert
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

6.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Experimental rabies in skunks: effects of immunosuppression induced by cyclophosphamide.

Authors:  K M Charlton; G A Casey; J B Campbell
Journal:  Can J Comp Med       Date:  1984-01

8.  Cells with natural killer activity in human rabies.

Authors:  T Panpanich; T Hemachudha; S Piyasirisilp; S Manatsathit; H Wilde; P Phanuphak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

9.  Mouse model for abortive rabies infection of the central nervous system.

Authors:  J S Smith
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

10.  Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus.

Authors:  Milosz Faber; Marie-Luise Faber; Jianwei Li; Mirjam A R Preuss; Matthias J Schnell; Bernhard Dietzschold
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.